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Mitochondrial quality control is essential to maintain
cellular homeostasis and is achieved by removing
damaged, ubiquitinated mitochondria via Parkin-
mediated mitophagy. Here, we demonstrate that
MYO6 (myosin VI), a unique myosin that moves
toward the minus end of actin filaments, forms a
complex with Parkin and is selectively recruited to
damaged mitochondria via its ubiquitin-binding
domain. This myosin motor initiates the assembly
of F-actin cages to encapsulate damaged mitochon-
dria by forming a physical barrier that prevents
refusion with neighboring populations. Loss of
MYO6 results in an accumulation of mitophago-
somes and an increase in mitochondrial mass. In
addition, we observe downstream mitochondrial
dysfunction manifesting as reduced respiratory ca-
pacity and decreased ability to rely on oxidative
phosphorylation for energy production. Our work un-
covers a crucial step in mitochondrial quality control:
the formation of MYO6-dependent actin cages that
ensure isolation of damaged mitochondria from the
network.
INTRODUCTION
Mitochondrial homeostasis involves the constant remodeling of
the mitochondrial network through fission and fusion events,
but also requires the isolation and subsequent removal of
dysfunctional mitochondria from this dynamic network.
Damaged organelles are then targeted for clearance via a
specialized selective autophagy pathway termed mitophagy
(Narendra et al., 2008). The E3 ubiquitin ligase Parkin (PARK2)
is a key regulator of the mitophagy pathway, and several forms
of autosomal recessive Parkinson’s disease are caused by
mutations in Parkin (Ryan et al., 2015). A hallmark of mitochon-484 Developmental Cell 44, 484–499, February 26, 2018 ª 2018 The
This is an open access article under the CC BY license (http://creativedrial damage is the loss of membrane potential resulting in
recruitment of Parkin to the outer mitochondrial membrane
(OMM), which extensively ubiquitinates OMM proteins thereby
amplifying the mitophagy signal (Nguyen et al., 2016). Cargo-
specific autophagy receptors (OPTN, NDP52, and TAX1BP1)
then recognize and capture ubiquitinated mitochondria via their
ubiquitin-binding domains and simultaneously bind to LC3 on
autophagosomal membranes via their LC3 interacting region
motif (Lazarou et al., 2015; Moore and Holzbaur, 2016;
Rogov et al., 2014; Wong and Holzbaur, 2014). Finally, the
dysfunctional, ubiquitinated mitochondria are sequestered into
double-membraned structures called autophagosomes, forming
mitophagosomes, which ultimately fuse with lysosomes for
degradation (Ktistakis and Tooze, 2016).
We have previously shown that TAX1BP1, NDP52, and OPTN
directly bind to myosin VI (MYO6) (Morriswood et al., 2007;
Sahlender et al., 2005), a unique highly specialized motor protein
that moves toward the minus end of actin filaments, in the
opposite direction to all other myosins (Wells et al., 1999). This
motor plays essential roles in regulating actin organization
(Mangold et al., 2011; Noguchi et al., 2006), and functions in
intracellular cargo sorting and vesicle transport linked to endocy-
tosis and autophagy (Buss et al., 1998, 2001; Dance et al., 2004;
Spudich et al., 2007; Tumbarello et al., 2012;Warner et al., 2003).
Specifically, we have shown that MYO6 is important in non-
selective and selective autophagy pathways for the clearance
of invading pathogens (xenophagy) and protein aggregates
(aggrephagy) (Tumbarello et al., 2012, 2015). These autophagy
defects were also observed in cells derived from the Snell’s
waltzer mouse, which lacks MYO6 due to a spontaneous intra-
genic deletion (Avraham et al., 1995; Tumbarello et al., 2012).
The intracellular localization and functions of MYO6 are medi-
ated by cargo adaptor proteins, which bind to specific sites in the
C-terminal cargo-binding domain (CBD) of the tail via either an
RRL motif (NDP52, OPTN, TAX1BP1, and GIPC) or a WWYmotif
(TOM1, LMTK2, and DAB2) (Bunn et al., 1999; Chibalina et al.,
2007; Morris et al., 2002; Morriswood et al., 2007; Sahlender
et al., 2005; Spudich et al., 2007; Tumbarello et al., 2012).
In addition, the tail of MYO6 can bind to ubiquitin and contains
a phospholipid-binding domain (He et al., 2016; PenengoAuthors. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. Endogenous and GFP-Tagged MYO6 Are Recruited to Damaged Mitochondria and Form a Complex with Parkin
(A) HA-Parkin-expressing HEK293 cells were treated for 2 h with 10 mMCCCP or left untreated. Images were acquired by superresolution structured illumination
microscopy (SR-SIM) after staining for endogenous MYO6, HA to detect Parkin, and cytochrome c (Cyt c) to visualize mitochondria.
(B) Quantitation of the percentage of cells with endogenous MYO6 on Cyt c-labeled mitochondria from (A) by widefield microscopy. Data are represented as
mean ± SEM. Two-tailed unpaired Student’s t test, ***p < 0.001, n = 3 (R427 cells per condition).
(C) Line profile of MYO6- and Parkin-positive mitochondrion along the white line indicated in (A).
(D) HEK293 cells stably expressing HA-Parkin transiently transfected with full-length (FL) GFP-MYO6 were left untreated or incubated for 2 h with
10 mM CCCP. Images were acquired by SR-SIM after staining for the GFP tag on MYO6, HA to detect Parkin, and TOMM20 to label the outer mitochondrial
membrane.
(E) Line profile of MYO6- and Parkin-positive mitochondrion along the white line indicated in (D).
(legend continued on next page)
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et al., 2006; Spudich et al., 2007). Using an unbiased mass
spectrometry approach, MYO6 and its endocytic cargo adaptor,
TOM1, were identified as proteins that associate with Parkin in
response to mitochondrial damage (Sarraf et al., 2013).
Taken together, this suggests a crucial link between MYO6
and its adaptor proteins to mitochondrial quality control mecha-
nisms including Parkin-mediated mitophagy. In this study, we
demonstrate that MYO6 is recruited via its ubiquitin-binding
domain and independently from the autophagy receptors to
damaged mitochondria by a Parkin-dependent mechanism.
We define a new quality-control step during mitophagy in which
MYO6, together with the actin regulator, cdc42, and actin nucle-
ators (Arp2/3 complex, formins, and N-WASP), promotes the as-
sembly of F-actin cages to encapsulate damaged mitochondria
within hours of the mitochondrial insult inhibiting their refusion
with neighboring populations. In addition, MYO6 functions in
the final stages of the pathway mediating the clearance of
damaged mitochondria via autophagy, as loss of MYO6 leads
to an accumulation of autophagosomes containing mitochon-
dria. We observe that the absence of MYO6 leads to profound
mitochondrial dysfunction, as cells lacking MYO6 accumulate
defective mitochondria. Hence, our evidence suggests that
MYO6 is a novel player inmitochondrial quality control andmain-
tenance of mitochondrial homeostasis.
RESULTS
MYO6 Is Recruited to Damaged Mitochondria and
Interacts with Parkin
First, we investigated whether MYO6 plays a role in the
clearance of damaged mitochondria by Parkin-mediated
mitophagy. Mitochondrial damage was induced either by
treating cells with the protonophore, carbonyl cyanide
3-chlorophenylhydrazone (CCCP), causing depolarization or
by using the electron transport chain complex III inhibitor,
antimycin A, in combination with oligomycin (an ATP synthase
inhibitor), which prevents mitochondrial repolarization. Both
treatments cause fragmentation of the mitochondrial network
and Parkin relocalization from the cytoplasm to the OMM
(Narendra et al., 2008). Using superresolution structured
illumination microscopy (SR-SIM), we observed that endoge-
nous MYO6, which normally resides on intracellular vesicles,
the plasma membrane, and in the cytosol (Buss et al., 1998;
Chibalina et al., 2007; Tumbarello et al., 2012; Warner et al.,
2003), was strongly recruited to and colocalized with Parkin-
positive damaged mitochondria stained for cytochrome c after
2 h of CCCP treatment in 90% of HEK293 cells expressing
Parkin (Figures 1A–1C) or after 3 h treatment with oligomy-
cin/antimycin A (OA) (Figure S1A).
GFP-tagged MYO6 also relocalized to the Parkin-positive
ring-like OMM and strongly colocalized with TOMM20 after
CCCP (Figures 1D and 1E) and also after OA treatment (Fig-(F) Parkin was immunoprecipitated using antibodies either against the HA tag or
CCCP or left untreated. The inputs, control immunoglobulin G (IgG) immunoprec
immunoprecipitation of endogenous MYO6. Actin is shown as a loading control.
(G) Endogenous MYO6 was immunoprecipitated from HA-Parkin-expressing HEK
control IP, and MYO6 IPs were immunoblotted for MYO6 as well as co-immunop
Images in (A), (D), (F), and (G) are representative of three independent experimen
486 Developmental Cell 44, 484–499, February 26, 2018ure S1B). MYO6 recruitment was Parkin dependent, since this
motor was not recruited to damaged mitochondria in HEK293
cells expressing Parkin, with the C431S mutation resulting in a
catalytically inactive E3 ligase that no longer targets tomitochon-
dria (Figure S1C).
To further analyze the link between MYO6 and Parkin, we
performed co-immunoprecipitation studies with antibodies to
Parkin or the hemagglutinin (HA) tag. Our results demonstrate
that Parkin forms a complex with MYO6 independent of CCCP
treatment (Figure 1F), which we also observed when we per-
formed the reverse by immunoprecipitating endogenous MYO6
(Figure 1G). Interestingly, the Parkin-MYO6 complex did not
involve the mitophagy receptors, OPTN, NDP52, and TAX1BP1,
as these were not co-immunoprecipitated with Parkin (data
not shown).
Taken together, we show that endogenous as well as ectopi-
cally expressed MYO6 translocate to the OMM upon mitochon-
drial stress in a Parkin-dependent manner and also associate
with Parkin independently of mitophagy induction and the
mitophagy receptors.
TheUbiquitin- andAutophagyReceptor-BindingDomain
of MYO6 Is Required for Parkin-Dependent Recruitment
to Damaged Mitochondria
To delineate which functional domain or protein-protein interac-
tion motif in MYO6 is responsible for recruitment to damaged
mitochondria, we transiently expressed GFP-taggedMYO6 con-
structs with specific point mutations in HeLaM cells and as-
sessed their level of recruitment to mitochondria by quantifying
the degree of colocalization between the GFP and TOMM20
channels (Figures 2A and 2B).
We first analyzed mutations in the motor domain: the K157R
mutation (rigor) in the ATP-binding site (P loop) of MYO6 that re-
sults in increased actin binding (Aschenbrenner et al., 2004) and
the D179Ymutation (tailchaser) in the transducer, which leads to
premature inorganic phosphate release from the head (Pyly-
penko et al., 2015). Both motor domain mutants and the tail of
MYO6 were sufficient for recruitment of MYO6 to mitochondria,
implying that motor activity is not required for this process (Fig-
ures 2B and S2). Point mutants in the motif interacting with
ubiquitin (A1013G) (Penengo et al., 2006) or the WWY motif
(W1202L) important for binding to DAB2, LMTK2, and TOM1
(Chibalina et al., 2007; Morris et al., 2002; Spudich et al., 2007;
Tumbarello et al., 2012), located in the CBD of the MYO6 tail
region are still recruited to damaged mitochondria. In contrast,
mutating the RRL motif (R1116A/R1117A/L1118A) responsible
for interactions with the autophagy receptors (TAX1BP1,
OPTN, and NDP52) and GIPC (Bunn et al., 1999; Morriswood
et al., 2007; Sahlender et al., 2005) or the MYO6 ubiquitin-
binding domain (MyUb, I1104A) (He et al., 2016) completely
abolished recruitment of GFP-taggedmutantMYO6 to damaged
mitochondria (Figures 2B and S2).Parkin from HA-Parkin-expressing HEK293 cells incubated for 1 h with 10 mM
ipitation (IP), and HA/Parkin IPs were immunoblotted for Parkin as well as co-
293 cells incubated for 1 h with 10 mMCCCP or left untreated. The inputs, IgG
recipitation of Parkin. Actin is shown as a loading control.
ts. See also Figure S1.
(legend on next page)
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In brief, these results demonstrate that MYO6 recruitment
does not require motor activity, but rather depends on a pro-
tein-protein interaction region in the tail domain that mediates
binding to autophagy receptors and/or ubiquitin.
MYO6 and the Autophagy Receptors Are Independently
Recruited to Damaged Mitochondria via Ubiquitin
We next elucidated whether binding of MYO6 to its known
adaptor proteins (the autophagy receptors), ubiquitin, or both
were responsible for recruiting MYO6 to damagedmitochondria.
TheMYO6bindingpartners TAX1BP1,OPTN,andNDP52have
previously been shown to be recruited to damaged mitochondria
as overexpressed and tagged proteins (Heo et al., 2015; Lazarou
et al., 2015; Moore and Holzbaur, 2016; Wong and Holzbaur,
2014). We followed the relocalization of the endogenous proteins
and found that TAX1BP1, similar to MYO6, is recruited to the
majority of Parkin-positive mitochondria, whereas OPTN, and
particularly NDP52, are recruited to foci on mitochondria
(Figure S3). Recruitment of the mitophagy receptors does not
require MYO6, since endogenous TAX1BP1, NDP52, and also
OPTN, are still targeted to damaged mitochondria in CRISPR/
Cas9 MYO6 knockout (KO) HeLaM cells (Figures S4A–S4D).
We subsequently analyzed whether binding of MYO6 to the
mitophagy receptors was required for bringing MYO6 to
damaged mitochondria by performing a triple small interfering
RNA (siRNA) knock down of TAX1BP1, NDP52, and OPTN
(TNO) in HeLaM cells. The efficient depletion of all three
mitophagy receptors enhanced GFP-MYO6 recruitment to
damaged mitochondria (Figures 2C–2E), possibly indicating
that, in the absence of the mitophagy receptors, more ubiquitin
chains attached to OMM proteins may be freely available to
MYO6. We have previously demonstrated that the ubiquitin-
binding domain overlaps with the MYO6-interacting region in
all three mitophagy receptors (see Figure S4E for TAX1BP1
schematic), and that single-point mutations that inhibit ubiquitin
binding also ablate MYO6 binding (Tumbarello et al., 2015).
Therefore, while bound to ubiquitin on the mitochondrial surface,
TAX1BP1, NDP52, or OPTN are no longer able to recruit MYO6Figure 2. MYO6 Binding to Ubiquitin, but Not to the Autophagy Rece
Mitochondria
(A) Illustration of MYO6 domain organization: catalytic motor domain (red), uniq
cargo-binding domain (CBD) in the tail region (blue). Enlarged is the CBD cont
ubiquitin-binding domains (motif interacting with ubiquitin [MIU], yellow; MYO6
mutations in different domains are highlighted.
(B) Quantitation of the degree of colocalization between the GFP-MYO6 construct
in HeLaM cells stably expressing HA-Parkin left untreated or incubated for 2 h wit
microscopy images. Data are represented as mean ± SEM. One-way ANOVA with
(C) HeLaM cells were treated with siRNA against TAX1BP1, NDP52, and OPTN (TN
and incubated for 2 h with 10 mM CCCP. Images were acquired by confocal micr
DsRed antibody, and Cyt c to visualize mitochondria.
(D) Western blot analysis of lysates corresponding to (C) confirming depletion of
mCherry-Parkin. a-Tubulin is shown as a loading control. Images in (C) and (D) a
(E) Quantitation of the degree of colocalization between GFP-MYO6 and Cyt c-
confocal microscopy images from (C). Data are represented as mean ± SEM. Tw
(F) Competition assay where GST-tagged MYO6 CBD (blue) and K63 tetra-ubiqu
(purple) and then incubated with increasing amounts of His-tagged TAX1BP1 (C
bodies against GST to detect MYO6, bound ubiquitin (P4D1), and bound TAX1BP
incubated with GSH sepharose to determine if there was any non-specific bin
demonstrate direct binding. Inputs of K63 Ub4 and His-TAX1BP1 (TAX1BP1 inpu
See also Figures S2–S4.
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binding (MyUb) domain. The observed loss in recruitment of
MYO6 to damagedmitochondria bymutating the RRLmotif (Fig-
ure 2B) is likely to be linked to destabilization of the MyUb
domain, as R1117 has been shown to be important for structural
integrity (He et al., 2016).
Having established that MYO6 is recruited to damaged mito-
chondria via its ubiquitin-binding domain, we next performed a
detailed analysis of MYO6 binding to polyubiquitin chains (Fig-
ure S4). We assessed the ability of purified His-tagged CBD of
MYO6 to bind ubiquitin chains of defined length in vitro. MYO6
bound strongly to K63 tetra-ubiquitin (Ub4) chains, but little bind-
ing to K11 Ub4 chains was observed (Figure S4F), in agreement
with published data using di-ubiquitin linkages (He et al., 2016).
Similarly, His-tagged TAX1BP1 also has a stronger preference
for binding to K63 compared with K11 Ub4 chains (Figure S4G).
Hence, MYO6 and TAX1BP1 both have the ability to bind K63
and, to a lesser extent, K11 ubiquitin chains in vitro. Since the
mitophagy receptor and ubiquitin-binding sites overlap and are
likely to be exclusive in the MYO6 CBD (He et al., 2016; Morris-
wood et al., 2007; Sahlender et al., 2005), we tested whether
increasing concentrations of His-TAX1BP1 are able to compete
with GST-MYO6 CBD prebound to K63 Ub4 chains in vitro. Inter-
estingly, we found that increasing amounts of TAX1BP1 did not
displace MYO6 CBD from the ubiquitin chains, but instead
bound to the K63 Ub4 chains forming a MYO6-ubiquitin-
TAX1BP1 complex (Figure 2F).
In summary, MYO6 and the mitophagy receptors, such as
TAX1BP1, are recruited independently and in parallel to ubiquitin
on the surface of damaged mitochondria, since their binding
sites are mutually exclusive. Thus, MYO6 appears to play a
role during mitophagy that is independent from, and does not
require, associations with the autophagy receptors.
MYO6 and Actin Regulators/Nucleators Assemble
F-Actin Cages around Damaged Mitochondria
Myosin motor proteins not only translocate along actin filaments
to generate movement and force, but they also actively regulateptors, Is Required for Parkin-Dependent Recruitment to Damaged
ue insert ‘‘reverse gear’’ (gray), IQ calmodulin-binding motif (orange), and a
aining two protein-protein interaction motifs (RRL, green; WWY, purple) and
ubiquitin-binding domain [MyUb], green). Amino acid residues of single point
s (wild-type [WT] or the indicated mutants) and TOMM20-labeled mitochondria
h 10 mMCCCP by determining the Pearson’s correlation coefficient of confocal
post-hoc Bonferroni correction, ***p < 0.001, nR 3 (R50 cells per condition).
O), then transiently transfected with GFP-MYO6 FL as well as mCherry-Parkin
oscopy after staining the GFP tag on MYO6, the mCherry tag on Parkin with a
TAX1BP1, NDP52, and OPTN, as well as overexpression of GFP-MYO6 and
re representative of three independent experiments.
labeled mitochondria by determining the Pearson’s correlation coefficient of
o-tailed paired Student’s t test, *p < 0.05, n = 3 (R100 cells per condition).
itin (Ub4) chains (yellow) were pre-incubated with glutathione (GSH) sepharose
-terminal half, pink). The samples were analyzed by immunoblotting with anti-
1. As controls, GST-MYO6 CBD, K63 Ub4, and His-TAX1BP1 were individually
ding. GST-MYO6 CBD and His-TAX1BP1 were also incubated together to
t) are also shown. Images are representative of four independent experiments.
(legend on next page)
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the dynamic turnover of the actin cytoskeleton. We therefore
investigated whether MYO6 recruitment was accompanied by
the assembly of an F-actin network around mitochondria in cells
stained with phalloidin. Using SR-SIM, we observed a dramatic
reorganization of the actin network and assembly of intricate
F-actin cages on Parkin-positive structures that surround
damaged mitochondria in HEK293 cells expressing Parkin
treated for 2 h with CCCP (Figures 3A, 3B, S5A, and S5B). The
assembly of these actin cages around damaged mitochondria
was also observed in HEK293 cells with endogenous Parkin after
6 h of CCCP treatment (Figures 5A and 5B).
The actin cytoskeleton has been reported to play an important
role in mitochondrial fission. Transient actin polymerization on
the OMM is known to occur within 2–5 min after C/FCCP treat-
ment, and these short-lived (<15min) actin filaments are required
for mitochondrial fission (Korobova et al., 2013; Li et al., 2015).
To determine the kinetics of MYO6 and F-actin recruitment to
damaged mitochondria, we performed a detailed time course
experiment to visualize MYO6 and F-actin assembly on
damagedmitochondria over time. Fiveminutes after CCCPaddi-
tion, we observed a rapid assembly of F-actin onmitochondria in
80% of cells, but no recruitment of endogenous as well as
GFP-tagged full-length MYO6 or the dominant-negative tail
(Figures 3C, 3D, 3F, and S5C). F-actin levels then drop and
only after prolonged treatment with CCCP (>1 h) is there a strong
increase in cells with MYO6 present on mitochondria concomi-
tant with a rise in F-actin by 2 h (Figures 3C–3F). These data
demonstrate that there are two waves of F-actin assembly on
mitochondria, the first one after 5 min independent of, and the
second one after 2 h dependent on, MYO6. This result is
supported by the finding that overexpression of the dominant-
negative MYO6 tail does not inhibit the assembly of mitochon-
drial F-actin induced after 5 min of CCCP treatment or the
process of mitochondrial fission; indeed, the mitochondrial
morphology of MYO6 tail-expressing cells under steady-state
conditions is network-like and similar to cells expressing GFP-
MYO6 FL (Figures 3G, 3H, and S5C). In short, although actin
filaments are essential for mitochondrial fission, we demonstrate
that MYO6 is not involved in this process. Mitochondrial recruit-
ment of MYO6 correlates only with the second wave of actin
assembly at a much later time point, which is consistent with
this being a distinct pathway.
To determine which actin regulators and nucleators are
involved in the assembly of F-actin cages around damaged
mitochondria, we used a panel of inhibitors against actin regula-Figure 3. Time Course of MYO6 and F-Actin Assembly around Damag
(A) HEK293 cells stably expressing HA-Parkin were left untreated or incubated f
endogenous MYO6, F-actin was visualized with phalloidin, and HA to detect Par
(B) Line profile of MYO6- and Parkin-positive mitochondrion that is F-actin-posit
(C) HA-Parkin-expressing HEK293 cells were left untreated or incubated for 5 min
endogenous MYO6, F-actin was visualized with phalloidin, and Cyt c as a mitoc
(D and E) Line profiles of F-actin-positive mitochondria along the white lines indic
positive after 2 h CCCP incubation (E).
(F) Quantitation of the percentage of cells with endogenous MYO6 or F-actin on
microscopy. Data are represented as mean ± SEM, n = 3 (R299 cells per condit
(G and H) Quantitation of the percentage of HA-Parkin-expressing HeLaM cells tra
10 mMCCCP (Figure S5C) that have F-actin onmitochondria (G) and fragmentedC
mean ± SEM. Two-tailed paired Student’s t test, ns, not significant, n = 3 (R213
Images in (A) and (C) are representative of three independent experiments. See a
490 Developmental Cell 44, 484–499, February 26, 2018tors (Rho [RhoI or Rhosin], Rac1 [NSC23766, W56 or EHT 1864],
and cdc42 [ML141]) and nucleators including the Arp2/3 com-
plex (CK666), formins (SMIFH2), and N-WASP (Wiskostatin).
Loss of cdc42 activity significantly reduced actin cage formation
as well as MYO6 recruitment around damaged mitochondria
after 2 h CCCP treatment, whereas inhibition of Rho and Rac1
using several different inhibitors had no effect (Figures 4A, 4B,
and S6). Moreover, the Arp2/3 complex, formins, and N-WASP
appear to be critical nucleators for actin cage assembly around
damaged mitochondria as their inhibition led to a complete
loss of actin and MYO6 on mitochondria in the majority of cells
(Figures 4A, 4B, and S6).
Furthermore, actin filament assembly around Parkin-positive
mitochondria after 2 h CCCP treatment requires full-length
MYO6 (Figures 4C and 4D), since overexpression of the domi-
nant-negative MYO6 tail, which still targets to mitochondria
(Figures 2B and S2) but can no longer bind to actin, inhibits the
formation of F-actin cages around damaged mitochondria (Fig-
ures 4C, 4E, and 4F). Unsurprisingly, MYO6 mutations, such as
K157R, D179Y, or A1013G, which target tomitochondria and still
bind to actin, do not inhibit F-actin assembly on damaged mito-
chondria (Figure 4F).
Taken together, these data show that MYO6 plays a crucial
role in the assembly of F-actin cages around damaged mito-
chondria, which is regulated by the Rho GTPase, cdc42, as
well as downstream nucleators, such as the Arp2/3 complex, for-
mins, and N-WASP. Our results demonstrate that two distinct
pathways for F-actin assembly on mitochondria after CCCP
treatment exist: a first wave (within minutes) of transient mito-
chondrial F-actin structures that mediate mitochondrial fission,
which is MYO6 independent, followed by a second wave
(after 2 h) leading to the formation of stable MYO6-dependent
F-actin cages around damaged mitochondria after mitophagy
induction concurrent with the recruitment of Parkin.
F-Actin Cages Inhibit Refusion of Fragmented
Mitochondria
To test whether MYO6-dependent F-actin cages are important
for isolating damaged mitochondria and preventing refusion
with neighboring populations, we analyzed the effect of these
actin structures on mitochondrial morphology and their ability
to fuse with other mitochondria after stress-induced fragmenta-
tion. To determine if there were any differences in the size of
mitochondria with or without F-actin cages, we quantitated the
mitochondrial area in HEK293 cells treated with CCCP for 6 hed Mitochondria
or 2 h with 10 mM CCCP. Images were acquired by SR-SIM after staining for
kin.
ive along the white line indicated in (A).
and 2 h with 10 mMCCCP. Images were acquired by SR-SIM after staining for
hondrial marker.
ated in (C) that are MYO6-negative after 5 min CCCP treatment (D) or MYO6-
Cyt c-labeled mitochondria from (C) at the indicated time points by widefield
ion).
nsiently transfected with GFP-MYO6, either FL or tail, incubated for 5 min with
yt c-labeledmitochondria (H) bywidefieldmicroscopy. Data are represented as
cells per condition).
lso Figure S5.
(legend on next page)
Developmental Cell 44, 484–499, February 26, 2018 491
(Figures 5A and 5B). Mitochondria surrounded by F-actin cages
are smaller in size compared with those lacking actin (Figure 5C).
On the contrary, in cells overexpressing the dominant-
negative MYO6 tail, which inhibits F-actin cage assembly (Fig-
ures 4C, 4E, and 4F), mitochondrial fragments were larger in
area compared with cells overexpressing full-length MYO6
(Figure 5D).
To confirm whether F-actin cages indeed inhibit refusion of
mitochondrial fragments and restrict mitochondrial fragment
size, we treated HEK293 cells expressing Parkin with CCCP for
2 h to generate the F-actin cages. In parallel, we inhibited actin
cage assembly by treating cells with the Arp2/3 inhibitor,
CK666 (Figure 4A). After washout of CCCP, we monitored
mitochondrial network reformation in a 3 h time course by wide-
field microscopy, and quantified the number of cells with either
(1) clustered, fragmented mitochondria, (2) refusing mitochon-
dria, or (3) an intact mitochondrial network (Figure 5E). The
absence of actin cages caused by CK666 significantly acceler-
ated refusion of fragmented mitochondria, with a concomitant
enhanced decrease in the clustered mitochondrial population
and increase in cells displaying mitochondrial network
morphology (Figure 5E). In summary, these results support our
hypothesis that the MYO6-induced F-actin cages trap and
isolate mitochondrial fragments by forming a physical barrier
around them that limits mitochondrial refusion and network
reformation (see our model, Figure 5F).
Loss of MYO6 Leads to Delayed Clearance of Damaged
Mitochondria by Parkin-Mediated Mitophagy
We next used electron microscopy (EM) to assess the impact of
MYO6 depletion onmitochondrial turnover by Parkin-dependent
mitophagy. We transiently expressed HA-Parkin in Snell’s
waltzer immortalized mouse embryonic fibroblasts (MEFs) that
lackMYO6 (Myo6sv/sv) as well as wild-type controls, and induced
mitophagy by CCCP treatment (Figure 6). To ensure that we
compared cells with matching expression levels of Parkin, which
regulates the rate of mitophagy, we performed correlative light
electron microscopy (CLEM). For this procedure, HA-Parkin
expression was first visualized by immunofluorescence, and
target cells expressing comparable Parkin levels identified by
confocal microscopy, whichwere subsequently analyzed by EM.
In wild-type, and also in Myo6sv/sv MEFs, we observed the
formation of phagophores and autophagosomes containing
either endoplasmic reticulum and cytoplasm or mitochondria
after 12 h of CCCP treatment indicating no defect in autophago-Figure 4. MYO6 and Actin Regulators/Nucleators Mediate the Assemb
(A and B) HEK293 cells stably expressing HA-Parkin were incubated for 2 h with
RhoI, or 50 mM Rhosin), Rac1 (100 mM NSC23766, 100 mM W56, or 10 mM EHT 1
CK666), formins (20 mMSMIFH2), or N-WASP (5 mMWiskostatin) (Figure S6). Quan
mitochondria by widefield microscopy. Data are represented as mean ± SEM.
significant, n R 3 (R339 cells per condition).
(C) HeLaM cells stably expressing HA-Parkin transiently transfected with GFP-M
acquired by SR-SIM after staining for the GFP tag onMYO6, with phalloidin to visu
three independent experiments.
(D and E) Line profiles of GFP-MYO6-positive mitochondria along the white lines i
negative for the tail (E).
(F) Quantitation of the percentage of HA-Parkin-expressing HeLaM cells express
with 10 mMCCCP that have F-actin on mitochondria by widefield microscopy. Da
post-hoc Bonferroni correction, ***p < 0.001, ns, not significant, n = 3 (R241 cel
492 Developmental Cell 44, 484–499, February 26, 2018some formation (Figure 6A). Our quantitation, however, revealed
a clear increase in the total number of autophagosomes in
Myo6sv/sv MEFs at 12 h after CCCP treatment, and a higher
proportion of autophagosomes containing mitochondria at
24 h after CCCP treatment (Figures 6A, panel d and 6B). This
block inmitophagosome clearance confirms our previous results
describing an overall accumulation of LC3-positive structures in
Myo6sv/sv MEFs by immunofluorescence and immunoblotting
(Tumbarello et al., 2012). Importantly, in contrast to wild-type
MEFs where mitophagosomes are degraded after 24 h of
CCCP treatment, Myo6sv/sv cells accumulate autophagosomes
containing damaged mitochondria (Figure 6B), implying a kinetic
delay in mitophagy.
Taken together, MYO6 is required at two stages of mitophagy:
(1) for the recruitment and assembly of F-actin cages around
damaged mitochondria to target these damaged organelles for
degradation bymitophagy, and (2) for thematuration ofmitopha-
gosomes to enable fusion with the lysosome for subsequent
degradation.
Cells Lacking MYO6 Accumulate Functionally Impaired
Mitochondria
To confirm the mitophagy defect in Myo6sv/sv MEFs, we first
measured the total mitochondrial mass by staining with the
MitoTracker Green FM dye, which is taken up by mitochondria
independent of their membrane potential and therefore labels
both healthy and damaged mitochondria. Flow cytometry re-
vealed a 50% increase in mitochondrial mass in Myo6sv/sv
MEFs compared with wild-type cells (Figure 7A), suggesting
that they have more mitochondria. We also observed striking
morphological changes in the hippocampal cortex of
16-month-old Snell’s waltzer mice starved overnight, where the
mitochondria inside astrocytes appear swollen compared with
those of wild-type mice (Figure S7). Although Myo6sv/sv cells
have more mitochondria, these also appear to be more
damaged, corroborating our EM results where we observe a
defect in the clearance of dysfunctional mitochondria by
mitophagy (Figure 6).
To assess the impact that loss of MYO6 has on overall mito-
chondrial homeostasis, we tested the functionality of mitochon-
dria in wild-type and Myo6sv/sv MEFs by measuring the oxygen
consumption rate, an indicator of mitochondrial respiration
(Figure 7B). MYO6-deficient cells had a significantly reduced
respiratory control ratio (refer to the STAR Methods), indicating
compromised mitochondrial function (Figure 7C). To furtherly of F-Actin Cages around Damaged Mitochondria
10 mM CCCP and inhibitors of actin regulators Rho (0.5 mg/mL Rho inhibitor I,
864), or cdc42 (20 mM ML141), and actin nucleators Arp2/3 complex (100 mM
titation of the percentage of cells with F-actin (A) and endogenousMYO6 (B) on
One-way ANOVA with post-hoc Bonferroni correction, ***p < 0.001, ns, not
YO6, either FL or tail, were incubated for 2 h with 10 mM CCCP. Images were
alize F-actin, and Cyt c as amitochondrial marker. Images are representative of
ndicated in (C) that are actin-positive in the case of GFP-MYO6 FL (D) or actin-
ing GFP-MYO6, either FL WT, tail, or the indicated mutants, incubated for 2 h
ta are represented as mean ± SEM. One-way repeated measures ANOVA with
ls per condition). See also Figure S6.
Figure 5. F-Actin Cages around Mitochondria Restrict Fragment Size and Lead to a Reduced Refusion Rate
(A) HEK293 cells with endogenous Parkin were left untreated or incubated for 6 h with 10 mMCCCP. Images were acquired by SR-SIM after staining F-actin with
phalloidin and Cyt c to label mitochondria. Images are representative of three independent experiments.
(B) Line profile of F-actin-positive mitochondrion along the white line in (A).
(C) Quantitation of the area of mitochondria that are actin positive (+) or negative (–) in regions of interest from cells imaged in (A). Data are represented as mean ±
SEM. Two-tailed paired Student’s t test, **p < 0.01, n = 17 from three independent experiments.
(D) Quantitation of the area of mitochondria in regions of interest with GFP-MYO6 FL (with actin) or tail (without actin) recruitment in HA-Parkin-expressing HeLaM
cells treated for 2 h with 10 mMCCCP and imaged in Figure 4C. Data are represented as mean ± SEM. Two-tailed unpaired Student’s t test, *p < 0.05, n = 18 from
three independent experiments.
(legend continued on next page)
Developmental Cell 44, 484–499, February 26, 2018 493
evaluate mitochondrial function in the presence and absence of
MYO6, we challenged MYO6 siRNA and mock-treated HEK293
cells with exogenous (Figures 7D–7F) or endogenous (Figures
7G–7I) Parkin expression by growing them in medium containing
galactose as the sole carbon source, which forces cells to rely on
mitochondrial oxidative phosphorylation (OXPHOS) for energy
generation. MYO6 knockdown cells displayed a slight growth
defect in glucose-containing medium, as previously reported,
most likely due to a defect in cytokinesis (Arden et al., 2007);
however, they still reached confluency (Figures 7D and 7G).
Whereas mock-treated cells grew at almost the same rate in
galactose medium as in standard medium with glucose, cells
depleted of MYO6 did not grow in galactose medium, indicative
of a mitochondrial defect (Figures 7E and 7H). Interestingly, we
made similar observations in HEK293 cells with endogenous
Parkin (Figures 7G–7I) compared with cells overexpressing
Parkin (Figures 7D–7F), indicating that MYO6, but not Parkin,
levels are critical to maintain a healthy population of functioning
mitochondria to enable cell growth in galactose medium (Figures
7E and 7H).
In short, our results demonstrate that, in the absence ofMYO6,
mitochondrial function is impaired and dysfunctional mitochon-
dria accumulate, implicating MYO6 as a novel player in mito-
chondrial quality control and maintenance of mitochondrial
homeostasis.
DISCUSSION
Here, we demonstrate a dual role for MYO6 in mitochondrial
quality control. First, we uncover a novel requirement for this
motor in organizing Parkin-dependent F-actin cages that isolate
damaged mitochondria to limit refusion with neighboring organ-
elles (Figure 5). Second, MYO6 mediates the clearance of
damaged mitochondria by Parkin-dependent mitophagy via its
associations with the mitophagy receptors, in particular the
maturation of mitophagosomes and fusion with lysosomes
(Tumbarello et al., 2012). Loss of MYO6 results in functionally
impaired mitochondria that have a reduced respiratory capacity,
andMYO6 knockdown cells failed to growwhen forced to rely on
mitochondrial OXPHOS (Figure 7). Although cells lacking MYO6
have more mitochondrial mass, these mitochondria appear
damaged, which we observe as swollen mitochondria in the
astrocytes of the hippocampal cortex of starved Snell’s waltzer
mouse brains (Figure S7), in agreement with the published liter-
ature (Osterweil et al., 2005). Thus, we demonstrate that the
absence of MYO6 leads to mitochondrial dysfunction. Interest-
ingly, some phenotypes of the MYO6 KOmouse, such as hyper-
trophic cardiomyopathy and gliosis in the brain (Mohiddin et al.,
2004; Osterweil et al., 2005), are reminiscent of mitochondrial(E) HA-Parkin-expressing HEK293 cells were treated for 2 h with 10 mMCCCP alo
hour for 3 h, stained with Cyt c to visualize mitochondria and DAPI to label nuclei,
categories of mitochondrial morphology: clustered, refusing, and network (repr
means ± SEM. Two-way repeated measures ANOVA with post-hoc Bonferroni c
(F) Schematic model on the role of MYO6 and F-actin: after a mitochondrial insult,
mitochondria, where it ubiquitinates outer mitochondrial membrane proteins. Su
ubiquitin chains (yellow), and damaged mitochondria are isolated in an F-actin
mitochondria serve as a barrier to prevent refusion with the mitochondrial network
complex, formins, and N-WASP.
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respectively.
We show that MYO6 recruitment to damaged mitochondria
after mitophagy induction and in the presence of Parkin does
not involve the mitophagy receptors. Instead, this motor is
directly targeted to mitochondria after OA or CCCP treatment
by binding to ubiquitin via its MyUb/RRL domain (Figures 1, 2,
S1A, and S1B). This ubiquitin-binding domain also encom-
passes the RRLmotif (He et al., 2016), which enables direct bind-
ing to the mitophagy receptors (TAX1BP1, NDP52, and OPTN)
(Morriswood et al., 2007; Sahlender et al., 2005). Intriguingly,
the MYO6 and ubiquitin-binding sites also overlap in TAX1BP1,
NDP52, and OPTN (Morriswood et al., 2007; Tumbarello et al.,
2015), suggesting that binding of MYO6 to the autophagy recep-
tors or to ubiquitin is mutually exclusive. These findings imply
that MYO6 and the mitophagy receptors are recruited indepen-
dently and in parallel to damaged mitochondria. This model is
supported by our results showing that translocation of TAX1BP1,
NDP52, or OPTN is not impaired in MYO6 KO cells generated by
CRISPR/Cas9 genome editing, and thatMYO6 is still recruited to
damaged mitochondria in cells depleted of all three mitophagy
receptors (Figures 2C and S4).
The recruitment of MYO6 via the MyUb/RRL domain is strictly
dependent on the presence of Parkin and its E3 ligase activity
(Figure S1C) that decorates the surface of mitochondria with
K63, K48, K6, and K11 ubiquitin chains (Cunningham et al.,
2015; Ordureau et al., 2014). Indeed, our in vitro studies demon-
strate that MYO6 can bind directly via the MyUb/RRL domain to
K63 and K11 tetramers, as shown previously for di-ubiquitin (He
et al., 2016), a similar ubiquitin chain preference as TAX1BP1
(Figure S4). Our in vitro competition assay demonstrates that
increasing amounts of TAX1BP1 bound to ubiquitin tetramers,
but did not displace MYO6, thus further highlighting the parallel
and independent recruitment of MYO6 and TAX1BP1 to
damaged mitochondria.
MYO6 is also in a complex with Parkin, as both proteins can be
co-immunoprecipitated in the presence or absence of CCCP
(Figure 1), thereby refining results from a large-scale interaction
proteomics study (Sarraf et al., 2013). Our data seem to suggest
that the MYO6-Parkin interaction is not dependent on recruit-
ment to mitochondria, but may also take place in other cellular
compartments. Indeed, the roles of Parkin are not restricted to
mitophagy, but also include regulation of cytokine secretion
and cell surface receptor endocytosis (de Léséleuc et al.,
2013; Fallon et al., 2006).
After CCCP treatment to induce mitochondrial damage, we
observe two distinct waves of F-actin assembly onmitochondria
(Figure 3). In agreement with previous studies, we show that the
dynamic and transient actin filament polymerization on the OMMne or with the addition of 100 mMCK666. After washout, cells were fixed every
and imaged by widefield microscopy. Images were scored according to three
esentative images taken by confocal microscopy). Data are represented as
orrection, *p < 0.05, **p < 0.01, n = 3 (R531 cells per time point).
the network fragments and Parkin (orange) is selectively recruited to damaged
bsequently, MYO6 (black) is recruited to damaged mitochondria by binding to
cage (red) from the neighboring population. F-actin cages around damaged
and require MYO6 as well as several actin regulators including cdc42, Arp2/3
Figure 6. Loss of MYO6 Leads to an Accumu-
lation of Damaged Mitochondria in Autopha-
gosomes after Mitophagy Induction
(A) Immortalized wild-type (Myo6+/+) and Snell’s
waltzer (Myo6sv/sv) mouse embryonic fibroblasts
(MEFs) were transiently transfected with HA-Parkin
and treated for 12 or 24 h with 20 mM CCCP. Cells
were imaged by confocal microscopy, processed for
correlative light electron microscopy, and imaged by
transmission electron microscopy. The star indicates
ruptured mitochondria and the arrow shows the
phagophore. Scale bars, 500 nm in subpanels (a, b,
e, and f), 1 mm in subpanels (c and d).
(B) Quantitation of the number of autophagosomes
containing mitochondria (white) or endoplasmic
reticulum and cytoplasmic material (black) in (A). At
least 19 randomly selected areas were counted per
cell type.
(C) Western blot analysis confirming the absence of
MYO6 from Snell’s waltzer immortalized MEFs
compared with wild-type lysates. Actin is shown as a
loading control. See also Figure S7.
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Figure 7. Cells Lacking MYO6 Accumulate Dysfunctional Mitochondria
(A) The mitochondrial mass of wild-type (Myo6+/+) and Snell’s waltzer (Myo6sv/sv) immortalized MEFs was measured using the MitoTracker Green FM dye by flow
cytometry. Data are represented as mean ± SEM. Two-tailed paired Student’s t test, *p < 0.05, n = 5.
(B) The oxygen consumption rate (OCR), an indicator of mitochondrial respiration, of wild-type and Snell’s waltzer immortalized MEFs was measured using the
XFe24 Extracellular Flux Analyser. Oligomycin (1 mM), FCCP (0.75 mM), and rotenone (1 mM) were injected at the indicated times to determine the oxygen
consumption rate at regular intervals. Normalized to rotenone as baseline. Data are represented as mean ± SEM, n = 3.
(C) Respiratory control ratio ([RCR]; OCR after FCCP addition divided by oligomycin) in wild-type and Snell’s waltzer immortalizedMEFs. Data are represented as
mean ± SEM. Two-tailed paired Students t test, *p < 0.05, n = 3.
(D–I) HEK293 cells stably expressing HA-Parkin (D and E) or HEK293 cells (G and H) were depleted of MYO6 by siRNA transfection and growth curves in
media containing (D and G) glucose (GLU) or (E and H) galactose (GAL) were obtained by quantitative live-cell phase contrast imaging. Data are represented
as mean ± SEM, n = 3. (F) Representative western blot analysis of lysates from (D) and (E) confirming depletion of MYO6 and similar expression levels of
Parkin. Actin is shown as a loading control. (I) Representative western blot analysis of lysates from (G) and (H) confirming depletion of MYO6 using actin as a
loading control.
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happens within 5 min of CCCP treatment, which is required for
mitochondrial fission (Korobova et al., 2013; Li et al., 2015).
Myosin II, which can assemble into bipolar filaments, is enriched
at these sites and is thought to provide the force for constriction
together with actin polymerization as inhibition of myosin II activ-
ity leads an increase in mitochondrial length (Hatch et al., 2014;
Korobova et al., 2014). However, MYO6 is not recruited at this
time point to mitochondria and is not required for mitochondrial
fission (Figures 3 and S5C).
In contrast to this immediate and short-lived actin response for
mitochondrial fission, we observe a MYO6- and Parkin-depen-
dent assembly of stable F-actin cages around fragmented
mitochondria a few hours after mitochondrial damage induction
with CCCP, which corresponds to the spatiotemporal recruit-
ment of MYO6 to damaged mitochondria (Figures 3, 4, and
S5). The formation of these actin structures on damaged
mitochondria is strongly inhibited in cells expressing the domi-
nant-negative MYO6 tail domain, indicating that full-length
MYO6 containing the motor domain is required for the organiza-
tion of F-actin cages around damaged mitochondria (Figure 4).
A role for this myosin in regulating actin filament dynamics and
assembly has been reported previously; for example, MYO6
has the capacity to promote the local accumulation of
actin structures at cell-cell contacts, such as the zonula
adherens of polarized epithelial cells (Mangold et al., 2011),
and in actin cones of segregating cells during Drosophila
spermatid individualization (Noguchi et al., 2006). Although the
exact mechanism of MYO6-dependent actin regulation is
currently not known, MYO6 has been identified in a complex
with DOCK7, a guanine nucleotide exchange factor for Rac
and cdc42, which performs important functions in the spatial
regulation of actin organization (Majewski et al., 2012; Sobczak
et al., 2016). In addition, we demonstrate a strong requirement
for cdc42, Arp2/3, formins, and N-WASP in F-actin cage forma-
tion around damaged mitochondria (Figure 4), suggesting tight
control of actin filament assembly around mitochondria.
Finally, we provide mechanistic insight into the functional
requirement of the F-actin cages recruited by MYO6. Loss of
these cages by overexpression of dominant-negative tails (Fig-
ure 4) results in largermitochondrial fragment size, and treatment
with the Arp2/3 inhibitor to prevent cage formation leads to an
increased rate of refusion after CCCP washout (Figure 5).
Thus, these MYO6-dependent actin cages isolate and quaran-
tine damaged mitochondria by forming a physical barrier to
inhibit refusion, and potentially content exchange, of damaged
subpopulations destined for mitophagy with neighboring organ-
elles. This actin-caging mechanism may therefore be a critical
quality control step to ensure mitochondrial homeostatic
regulation.
Conclusions
We have identified essential roles for MYO6 in mitochondrial
turnover and homeostasis. The loss of MYO6 leads to reduced
clearance of autophagosomes containing mitochondria, and
causes the accumulation of damaged mitochondria with
impaired respiratory capacity. Cells without MYO6 are no longer
able to grow in galactose medium, which requires fully functional
mitochondria for energy production via OXPHOS. We propose a
dual role for MYO6 in Parkin-dependent mitophagy. Firstly,MYO6 is recruited via ubiquitin directly to mitochondria, where
it induces the formation of F-actin cages, which serve as a quality
control mechanism to quarantine damaged mitochondria and
prevent refusion with neighboring populations after mitophagy
induction (Figure 5F). Secondly, the maturation of autophago-
somes containing mitochondria to enable lysosomal degrada-
tion is mediated byMYO6, in agreement with our previousmodel
(Tumbarello et al., 2012, 2013).
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB HEK293 Cell Culture
B HeLaM Cell Culture





B Generation of Stable Cell Lines
B Mouse Genotyping and Establishment of Immortalized
Mouse Embryonic Fibroblasts
B Western Blot and Co-Immunoprecipitation
B Immunofluorescence and Confocal/Widefield Mi-
croscopy
B Superresolution Structured Illumination Microscopy
(SR-SIM)
B Electron Microscopy (EM)
B Flow Cytometry
B Measurement of Mitochondrial Respiration
B Growth Curves by Quantitative Live-Cell Phase
Contrast Imaging
B Protein Expression and Purification
B Ubiquitin Binding and Competition Assays
B Presentation of Data




Supplemental Information includes seven figures and can be found with this
article online at https://doi.org/10.1016/j.devcel.2018.01.007.
ACKNOWLEDGMENTS
We thank Matthew Gratian and Mark Bowen from the CIMR microscopy core
facility supported by the Wellcome Trust with a strategic award (100140) and
equipment grant (093026). We also thank Reiner Schulte from the CIMR
flow cytometry core facility for advice and discussions. We are grateful to
David Tumbarello for help with mouse perfusions and dissections. F.B. thanks
the Medical Research Council (MR/K000888/1 and MR/N000048/1), the
British Heart Foundation (PG/15/12/31280), the Biotechnology and Bio-
logical Sciences Research Council (BB/K001981/1), and, together with
A.J.K., the Michael J. Fox Foundation for Parkinson’s Research for financial
support. J.K.-J. (U105184323), J.E.R., and M.M. (U105697135 andDevelopmental Cell 44, 484–499, February 26, 2018 497
RG89175/SMAG/005) are supported by the Medical Research Council. J.A.N.
is a Wellcome Trust Senior Clinical Research Fellow (102770/Z/13/Z).
AUTHOR CONTRIBUTIONS
A.J.K. designed, performed, and analyzed the experiments with the following
exceptions: C.K.-I. performed electron microscopy experiments, T.A.M.
performed some superresolution structured illumination microscopy, J.K.-J.
prepared recombinant proteins and antibodies, J.A.N. conceived and G.L.G.
conducted ubiquitin binding and competition experiments, M.M. conceived
and J.E.R. gave technical advice for extracellular flux analyzer and incucyte
experiments. F.B. designed and conceived the study. F.B and A.J.K. wrote
the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: January 27, 2017
Revised: October 30, 2017
Accepted: January 8, 2018
Published: February 1, 2018
REFERENCES
Arden, S.D., Puri, C., Au, J.S., Kendrick-Jones, J., and Buss, F. (2007). Myosin
VI is required for targeted membrane transport during cytokinesis. Mol. Biol.
Cell 18, 4750–4761.
Arden, S.D., Tumbarello, D.A., Butt, T., Kendrick-Jones, J., and Buss, F.
(2016). Loss of cargo binding in the human myosin VI deafness mutant
(R1166X) leads to increased actin filament binding. Biochem. J. 473,
3307–3319.
Aschenbrenner, L., Naccache, S.N., and Hasson, T. (2004). Uncoated endo-
cytic vesicles require the unconventional myosin, Myo6, for rapid transport
through actin barriers. Mol. Biol. Cell 15, 2253–2263.
Avraham, K.B., Hasson, T., Steel, K.P., Kingsley, D.M., Russell, L.B.,
Mooseker, M.S., Copeland, N.G., and Jenkins, N.A. (1995). The mouse
Snell’s waltzer deafness gene encodes an unconventional myosin required
for structural integrity of inner ear hair cells. Nat. Genet. 11, 369–375.
Bond, L.M., Arden, S.D., Kendrick-Jones, J., Buss, F., and Sellers, J.R. (2012).
Dynamic exchange of myosin VI on endocytic structures. J. Biol. Chem. 287,
38637–38646.
Brooks, A.B.E., Humphreys, D., Singh, V., Davidson, A.C., Arden, S.D., Buss,
F., and Koronakis, V. (2017). MYO6 is targeted by Salmonella virulence effec-
tors to trigger PI3-kinase signaling and pathogen invasion into host cells. Proc.
Natl. Acad. Sci. USA 114, 3915–3920.
Bunn, R.C., Jensen, M.A., and Reed, B.C. (1999). Protein interactions with the
glucose transporter binding protein GLUT1CBP that provide a link between
GLUT1 and the cytoskeleton. Mol. Biol. Cell 10, 819–832.
Buss, F., Arden, S.D., Lindsay, M., Luzio, J.P., and Kendrick-Jones, J. (2001).
Myosin VI isoform localized to clathrin-coated vesicles with a role in clathrin-
mediated endocytosis. EMBO J. 20, 3676–3684.
Buss, F., Kendrick-Jones, J., Lionne, C., Knight, A.E., Côté, G.P., and Paul
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal to actin Sigma-Aldrich Cat# A2066; RRID AB_476693
Mouse monoclonal to cytochrome c, clone 6H2.B4 BioLegend Cat# 612302; RRID AB_315775
Rabbit polyclonal to DsRed Clontech Laboratories Cat# 632496; RRID AB_10013483
Mouse monoclonal to GFP, clone 9F9.F9 Abcam Cat# ab1218; RRID AB_298911
Rabbit polyclonal to GFP Thermo Fischer Scientific Cat# A-11122; RRID AB_221569
Rabbit polyclonal to GFP Abcam Cat# ab6556; RRID AB_305564
Rabbit polyclonal to GST Sigma-Aldrich Cat# G7781; RRID AB_259965
Mouse monoclonal to HA, clone HA-7 Sigma-Aldrich Cat# H9658; RRID AB_260092
Rat monoclonal to HA, clone 3F10 Roche Cat# 11867423001; RRID AB_390918
Rabbit polyclonal to optineurin (Ab2) Sigma-Aldrich Cat# HPA003360; RRID AB_1079528
Mouse monoclonal to parkin, clone PRK8 Santa Cruz Biotechnology Cat# sc-32282; RRID AB_628104
Rabbit polyclonal to Tom20 (FL-145) Santa Cruz Biotechnology Cat# sc-11415; RRID AB_2207533
Mouse monoclonal to a-tubulin, clone DM1A Sigma-Aldrich Cat# T9026; RRID: AB_477593
Mouse monoclonal to ubiquitin, clone FK2 Millipore Cat# ST1200; RRID: AB_10681625
Affinity-purified rabbit polyclonal to MYO6 (Buss et al., 1998) N/A
Affinity-purified rabbit polyclonal to TAX1BP1 (Morriswood et al., 2007) N/A
Affinity-purified rabbit polyclonal to NDP52 (Morriswood et al., 2007) N/A
Affinity-purified rabbit polyclonal to OPTN (Sahlender et al., 2005) N/A
Bacterial and Virus Strains
HA-Parkin/pMXs-IP (Yoshii et al., 2011) Addgene;
Cat# 38248
HA-Parkin C431S/pMXs-IP This paper N/A
Chemicals, Peptides, and Recombinant Proteins
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) Fischer Scientific Cat# AC228131000
Oligomycin Millipore Cat# 495455
Antimycin A Sigma-Aldrich Cat# A8674
K63 tetraubiquitin (Ub4) Boston Biochem Cat# UC-310
K11 Ub4 (Grice et al., 2015) N/A
Rhosin Calbiochem Cat# 555460
Rho inhibitor I Cytoskeleton Cat# CT04
NSC23766 trihydrochloride Sigma-Aldrich Cat# SML0952
EHT 1864 Tocris Bioscience Cat# 3872
W56 Tocris Bioscience Cat# 2221
ML141 Sigma-Aldrich Cat# SML0407
CK666 Abcam Cat# ab141231
Formin FH2 Domain Inhibitor (SMIFH2) Calbiochem Cat# 344092
Wiskostatin Sigma-Aldrich Cat# W2270
Critical Commercial Assays
Seahorse XF Cell Mito Stress Test Kit Agilent Technologies Cat# 103015-100
Experimental Models: Cell Lines
Human HEK293 ECACC Cat# 85120602
HA-Parkin expressing HEK293 This paper HA-Parkin/HEK293
HA-Parkin C431S expressing HEK293 This paper HA-Parkin C431S/HEK293
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Human HeLaM Roger Tsien, University of
California San Diego
N/A
HA-Parkin expressing HeLaM This paper HA-Parkin/HeLaM
CRISPR/Cas9 MYO6 knockout HeLaM (Brooks et al., 2017) N/A
Wild-type (Myo6+/+) immortalized MEF This paper N/A
Snell’s waltzer (Myo6sv/sv) immortalized MEF This paper N/A
Experimental Models: Organisms/Strains
Mouse: C57BL/6 wild-type (Myo+/+) and Snell’s
waltzer (Myo6sv/sv)
(Avraham et al., 1995) N/A
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Parkin WT/pEGFP-C2 (Trempe et al., 2013) Addgene;
Cat# 45875





Full-length (FL) human (h) MYO6 (isoform 5
containing no alternative splicing inserts,
UniProtKB: Q9UM54-5) wild type (WT)/pEGFP-C3
(Bond et al., 2012) GFP-MYO6 FL
hMYO6 FL K175R* (rigor)/pEGFP-C3
* all amino acid designations are according to
the canonical human MYO6 sequence
(isoform 3, UniProtKB: Q9UM54-3)
(Arden et al., 2016) GFP-MYO6 FL K175R
hMYO6 FL A1013G (MIU)/pEGFP-C3 (Tumbarello et al., 2012) GFP-MYO6 FL A1013G
hMYO6 FL R1116A/R1117A/L1118A
(RRL)/pEGFP-C3
(Arden et al., 2016) GFP-MYO6 FL RRL
hMYO6 FL W1202L (WWY)/pEGFP-C3 (Arden et al., 2016) GFP-MYO6 FL WWY
hMYO6 tail/pEGFP-C3 (Chibalina et al., 2010) GFP-MYO6 tail
hMYO6 FL I1104A (MyUb)/pEGFP-C3 This paper GFP-MYO6 FL I1104A
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REAGENT or RESOURCE SOURCE IDENTIFIER
hMYO6 FL D179Y (tailchaser)/pEGFP-C3 This paper GFP-MYO6 FL D179Y
hTAX1BP1 (isoform 2, UniProtKB: Q86VP1-2;
aa 425–789x)/pRSET-A
x all amino acid designations are according to
the canonical TAX1BP1 sequence (isoform 1,
UniProtKB Q86VP1-1)
(Morriswood et al., 2007) His-TAX1BP1
(C-terminal half)
hMYO6 cargo binding domain (CBD, aa
1034–1294)/pGEX-4T1
(Arden et al., 2016) GST-MYO6 CBD
hMYO6 CBD/pRSET-A This paper His-MYO6 CBD
Software and Algorithms
Prism GraphPad N/A




Seahorse XFe Wave Agilent Technologies N/A
IncuCyte 2011A Essen Bioscience N/A
Photoshop, InDesign, Illustrator Adobe N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Folma
Buss (fb207@cam.ac.uk). MTAs were obtained for all Addgene constructs.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All cells were incubated at 37C and 5% CO2.
HEK293 Cell Culture
HEK293 cells were grown in MEM (M2279, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, F7524, Sigma-Aldrich),
1% non-essential amino acids (M7145, Sigma-Aldrich), 2 mM L-glutamine (G7513, Sigma-Aldrich), 100 U/ml penicillin and 100 mg/ml
streptomycin (P4333, Sigma-Aldrich).
HeLaM Cell Culture
HeLaM and CRISPR/Cas9 MYO6 knockout HeLaM (Brooks et al., 2017) were cultured in RPMI-1640 (R8758, Sigma-Aldrich)
containing 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. Immortalized MEFs were maintained in DMEM (31966-021,
Thermo Fischer Scientific) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Snell’s Waltzer Mice
The Snell’s waltzer mice (C57BL/6 background) were bred and housed under pathogen-free conditions in the animal facility at
Cambridge University. Experimentation involving animals was carried out under a UK Home Office Project Licence granted to Dr
Folma Buss (PPL 70/8460) and was approved by the UK Home Office and the University of Cambridge Animal Welfare and Ethical
Review Committee. The work has been carried out in accordance to the UK Animals (Scientific Procedures) Act 1986 and follows the
Laboratory Animal Science Association (LASA) Guidelines.
METHOD DETAILS
Antibodies
The antibodies listed in the Key Resources Table were used as follows: rabbit polyclonal antibody to actin (A2066, Sigma-Aldrich,WB
1:2,000), mouse monoclonal to cytochrome c (6H2.B4, 612302, BioLegend, IF 1:200), rabbit polyclonal to DsRed (632496, Clontech
Laboratories, IF 1:500, WB 1:1,000), mouse monoclonal to GFP (9F9.F9, ab1218, abcam, IF 1:400–1,000), rabbit polyclonal to GFP
(A11122, Thermo Fischer Scientific, IF 1:400), rabbit polyclonal to GFP (ab6556, abcam, WB 1:1,000), rabbit polyclonal to GST
(G7781, Sigma-Aldrich, WB 1:20,000), mouse monoclonal to HA (HA-7, H9658, Sigma-Aldrich, IP), rat monoclonal to HA (3F10,
11867423001, Roche, IF 1:100, IP), rabbit polyclonal to optineurin (Ab2, HPA003360, Sigma-Aldrich, IF 1:100), mouse monoclonale3 Developmental Cell 44, 484–499.e1–e6, February 26, 2018
to parkin (PRK8, sc-32282, Santa Cruz Biotechnology, WB 1:500), rabbit polyclonal to Tom20 (FL-145, sc-11415, Santa Cruz
Biotechnology, IF 1:100), mouse monoclonal to a-tubulin (DM1A, T9025, WB 1:2,000), mouse monoclonal to ubiquitin (P4D1,
sc-8017, Santa Cruz Biotechnology, WB 1:1,000), mouse monoclonal to ubiquitin (FK2, ST1200, Millipore, WB 1:1,000). Affinity-
purified rabbit polyclonal antibodies against MYO6, TAX1BP1, NDP52, and OPTN (IF 1:100, WB 1:1,000) were generated as
previously described (Buss et al., 1998; Morriswood et al., 2007; Sahlender et al., 2005).
Plasmids
The construct to express catalytically inactive HA-Parkin harboring the C431Smutation in cells was generated by site-directedmuta-
genesis (SDM) of the HA-Parkin/pMXs-IP construct using the Parkin_C431S_For and Parkin_C431S_Rev primers listed in the Key
Resources Table. By SDM of full-length (FL) human (h) MYO6 in the pEGFP-C3 vector, the MyUb mutant (I1104A) was generated
using MYO6_I1104A_For and MYO6_I1104A_Rev primers and the tailchaser mutant (D179Y) using the MYO6_D179Y_For and
MYO6_D179Y_Rev primers listed in the Key Resources Table. Human MYO6 CBD (aa 1034–1294) was amplified by PCR using
hMYO6 FL/pEGFP-C3 as a template with the MYO6_CBD_For and MYO6_CBD_Rev primers and cloned into pRSET-A using
XhoI/EcoRI sites. All constructs were verified by sequencing (Source BioScience).
Transfections
Transient DNA transfections were performed using FuGENE 6 (Promega) according to the manufacturer’s instructions. For efficient
knockdown, cells were transfected twice with ON-TARGETplus SMARTpool siRNA oligonucleotides (Dharmacon, GE) against
human MYO6, TAX1BP1, NDP52, or OPTN using Oligofectamine (Thermo Fischer Scientific) on day 1 and 3. For the mock transfec-
tion, the siRNA was replaced with Opti-MEM (Thermo Fischer Scientific). If required, cells were transfected with DNA constructs on
day 4. On day 5, the cells were processed for the corresponding assay and the efficiency of protein depletion assessed by Western
blotting.
Generation of Stable Cell Lines
HEK293 and HeLaM cells stably overexpressing HA-Parkin WT or HA-Parkin C431S were generated by retroviral transduction of the
HA-Parkin WT or C431S constructs in the pMXs-IP vector. Single-cell clones were selected with 1 mg/ml puromycin (Thermo Fischer
Scientific) and these stable cell lines were maintained in HEK293 or HeLaM medium supplemented with 1 mg/ml puromycin.
Mouse Genotyping and Establishment of Immortalized Mouse Embryonic Fibroblasts
Wild-type and Snell’s waltzer C57BL/6J mice (Avraham et al., 1995) were genotyped using a PCR-based method (Self et al., 1999)
with modifications. Genomic DNA from tails was isolated using the High Pure PCR Template Preparation Kit (Roche) and amplified
with ex18F and ex19R primers listed in the Key Resources Table that flank the deletion in the sv allele. Wild-type (Myo+/+) mice dis-
played a genomic fragment of 2.3 kb and Snell’s waltzer (Myo6sv/sv) mice displayed a 1.3 kb fragment, while heterozygous mice
generated both fragments. Primary embryonic fibroblasts from wild-type and Snell’s waltzer mice were prepared as previously
described (Warner et al., 2003) and immortalized with the SV40 large T-antigen (pEF321-T) by transfection with Lipofectamine
2000 (Thermo Fischer Scientific). The media was changed after 24 hours (h) and cells were expanded over several weeks to
make mixed immortalized MEF cultures.
Western Blot and Co-Immunoprecipitation
Cell lysates were prepared in ice-cold RIPA lysis buffer (1% Triton, 0.1% SDS, 1% DOC, 150 mM NaCl, 10 mM Tris, pH 7.4, 5 mM
EDTA) containing protease inhibitors (cOmpletemini, EDTA-free, Roche), boiled in SDS loading buffer, and separated by SDS-PAGE.
After protein transfer on to PVDF (Immobilon-P, Millipore), the membrane was blockedwith 5% fat-freemilk powder in PBS-T (0.05%
Tween-20 in PBS) for 1 h at room temperature (RT) and incubated with primary antibodies overnight at 4C. The membranes were
washed three times with PBS-T and incubated with the corresponding HRP-conjugated secondary antibody for 1 h at RT. After
washing as before, the protein bands were detected with ECL or ECL Prime Western blotting detection reagent (GE Healthcare
Life Sciences) according to the manufacturer’s protocol and exposed to X-ray film (Fujifilm).
Co-immunoprecipitation experiments were performed from HA-Parkin WT/HEK293 stable cell lines under native conditions. Cells
were collected in ice-cold native lysis buffer [50 mM Tris, pH 7.4, 100 mM NaCl, 1% NP-40, 5 mM MgCl2, 5 mM ATP (Roche) sup-
plemented with protease inhibitors (cOmplete mini, EDTA-free, Roche), phosphatase inhibitors (PhosSTOP, Roche), 1 mM PMSF
(Viva Bioscience), 1 mM NEM, 1 mM IAA] and cell debris pelleted at 20000 3g for 15 min. The supernatants were precleared with
either Protein A or G sepharose beads for 1 h, incubated with 5 mg antibody for 1 h, and subsequently with Protein A or G sepharose
beads for 1 h at 4C with end-over-end mixing. The beads were washed four times with 0.2% NP-40 in TBS, once with TBS, and
protein complexes were eluted off the beads with 5X SDS loading buffer before separation by SDS-PAGE and immunoblotting.
Immunofluorescence and Confocal/Widefield Microscopy
Cells plated on glass coverslips were washed with PBS and fixed with 4% formaldehyde (Electron Microscopy Sciences) for 20 min,
washed three timeswith PBS, and permeabilizedwith 0.2%Triton X-100 in PBS for 2min. After blocking in 1%BSA in PBS for 30min,
cells were incubated with primary antibodies for 1 h at RT in a humidified chamber. After three washes with PBS and incubation with
the appropriate AlexaFluor 488-, 568-, 647-conjugated species-specific secondary antibodies (1:300, Thermo Fischer Scientific) orDevelopmental Cell 44, 484–499.e1–e6, February 26, 2018 e4
AlexaFluor 488/568-conjugated phalloidin (1:1000, Thermo Fischer Scientific) for 45 min, coverslips were mounted with ProLong
Gold Antifade (Thermo Fischer Scientific). Images were acquired on LSM 710 or LSM 880 confocal microscopes (Carl Zeiss
Microscopy) with ZEN Black (Carl Zeiss Microscopy) software or an AxioImager Z2 widefield microscope with ZEN Blue (Carl Zeiss
Microscopy) software.
Superresolution Structured Illumination Microscopy (SR-SIM)
Acid-washed high performance coverslips (#1.5H, thickness 170±5 mm, Schott) were used, processed for immunofluorescence as
above with the exception of using eight times the concentration of fluorescently labelled phalloidin (1:50) and mounting on unfrosted
glass microscope slides (Thermo Fischer Scientific) followed by curing for three days at room temperature in the dark prior to
imaging. Z-stacks were acquired at five phases and five rotations of the illumination grid on an ELYRA PS.1 superresolution
microscope (Carl Zeiss Microscopy). The images were processed and channel aligned using ZEN Black ELYRA edition (Carl Zeiss
Microscopy). Line profiles on single slices were generated in ZEN Black and normalized for each channel.
Electron Microscopy (EM)
For correlative light and electron microscopy (CLEM), MEFs transiently expressing HA-Parkin were cultured on glass bottom dishes
with a grid pattern (P35G-2-14-C-GRID, MatTek) and treated with 20 mM CCCP for 12 h or 24 h (Kishi-Itakura and Buss, 2017). The
cells were fixed with 4% formaldehyde (F017, TAAB) in 0.1 M sodium phosphate buffer (PB, pH 7.4) for 2 h, washed with the same
buffer three times, and incubated for 15 seconds (s) in PB containing 14% glycerol and 35% sucrose. After permeabilization by
freezing and thawing in liquid nitrogen for 15 s, cells were immunostained with anti-HA antibody followed by Alexa Fluor 488 anti-
rat secondary antibody as well as Hoechst and examined under a LSM 780 confocal microscope. The same specimens were further
incubated with 2% formaldehyde and 2.5% glutaraldehyde (G011/2, TAAB) in 0.1 M PB for 2 h. After three washes in 0.1 M PB, the
samples were post-fixed with 1.5% osmium tetroxide in 0.1 M PB for 2 h, dehydrated in ethanol, and embedded in Agar 100 mixture
(Agar Scientific). Ultrathin sections (70 nm thick) were stained with saturated uranyl acetate and lead citrate solution and observed
under a FEI Tecnai Spirit transmission electron microscopy (TEM). Images were recorded with a Gatan CCD camera (Gatan US
1000X-U Camera 2000 kV).
For conventional EM analysis of mouse brains, 16-month old mice were starved overnight and fixed by cardiac perfusion using
Ringer’s buffer and then 2% glutaraldehyde and 2% formaldehyde in 30 mM HEPES (pH 7.4) buffer as previously described
(Takamura et al., 2011). Subsequently, the mouse brains were embedded in 5% low melting point agarose (A4018) in 0.1 M PB
and glued to the sectioning block of a vibratome. The sections (0.3–0.4 mm thick) were post-fixed with 1.5% osmium tetroxide in
0.1 M PB for 2 h. Tissues were dehydrated in a graded series of ethanol and embedded in Agar 100 mixture. Ultrathin sections
were processed for EM analysis as above.
Flow Cytometry
For mitochondrial mass measurements, wild-type (Myo6+/+) and Snell’s waltzer (Myo6sv/sv) immortalized MEFs were seeded at
200,000 cells/well and after 48 h, were incubated with 100 nM MitoTracker Green FM dye (Thermo Fischer Scientific) for 45 min
at 37C and 5% CO2. Cells were collected by trypsinization, washed and resuspended in PBS, and analyzed immediately by flow
cytometry using 488 nm laser (excitation) with 530/30 nm band pass filter (emission) on a BD LSRFortessa. The data was analysed
using FlowJo software (vX.0.7) where debris and apoptotic cells were excluded using forward and side scatter gating.
Measurement of Mitochondrial Respiration
Wild-type (Myo6+/+) and Snell’s waltzer (Myo6sv/sv) immortalized MEFs were seeded in quintuplicate at 40,000 cells/well in 100 ml
growth medium in Seahorse XF24 cell culture microplates (Agilent Technologies) and incubated for 24 h at 37C and 5% CO2.
One hour before the assay, growth medium was removed, replaced with 630 ml assay medium [XF assay medium (102352-000,
Seahorse Bioscience), pH 7.4, supplemented with 5 mM D(+)-galactose (G5388) and 1 mM sodium pyruvate (11360-039, Thermo
Fischer Scientific)], and left to stabilize in a 37C incubator without CO2. The wells containing cells were sequentially injected with
70 ml of 10 mM oligomycin (final: 1 mM) to inhibit ATP synthase, 8.25 mM FCCP (final: 0.75 mM) to uncouple the respiratory chain,
12 mM rotenone (final: 1 mM; all inhibitors were part of the Seahorse XF Cell Mito Stress Test Kit, Agilent Technologies) to inhibit
complex I and the oxygen consumption rate (OCR) was measured every 5 min using an XFe24 Extracellular Flux Analyzer with
XFe Wave software (Seahorse Bioscience) (Rorbach et al., 2012). The Respiratory Control Ratio (RCR) was calculated by dividing
the OCR after FCCP injection by that after oligomycin addition.
Growth Curves by Quantitative Live-Cell Phase Contrast Imaging
HEK293 or HA-Parkin expressing HEK293 cells were grown in either DMEM (31966-021, Thermo Fischer Scientific) containing 10%
FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin or DMEM (11966-025, Thermo Fischer Scientific) containing 10% FBS, 1 mM
sodium pyruvate, 10 mM D(+)-galactose, 100 U/ml penicillin, and 100 mg/ml streptomycin during the knockdown procedure
(see above). On day 3, cells were seeded in a 6-well plate at 150,000 cells/well in glucose medium or 250,000 cells/well in galactose
medium and reverse transfected with siRNA against MYO6. Growth curves were obtained using the IncuCyte HD live-cell imaging
system (Essen Bioscience), which photographed cells in phase contrast every 8 h for >4 days (Rorbach et al., 2014), and analysed
with the IncuCyte 2011A software (Essen Bioscience).e5 Developmental Cell 44, 484–499.e1–e6, February 26, 2018
Protein Expression and Purification
K11 tetraubiquitin (Ub4) was synthesized using the E2 enzyme Ube2S as described previously (Grice et al., 2015). Human TAX1BP1
(aa 425–789) was cloned into the pRSET-A vector (Morriswood et al., 2007) and the His-tagged protein expressed in E. coliC41 (DE3)
cells. The bacteria were initially grown at 37C for 5 h (until an optical density of 1.0 at A600 nm), then cooled to 20C, induced with
1 mM isopropyl b-D-1 thiogalactopyranoside (IPTG, Melford) and then grown at 20C for a further 17–24 h. After cooling, the bacteria
were pelleted by centrifugation at 2,500 3 g for 30 min. The cell pellets were frozen in liquid nitrogen, thawed, resuspended in lysis
buffer (PBSwith 200mMNaCl, 50mM imidazole, 15mM b-mercaptoethanol), sonicated and centrifuged at 600003 g for 30min. The
lysis supernatant was added to equilibrated Ni-NTA agarose resin (Qiagen), washed extensively with lysis buffer and the His-tagged
hTAX1BP1 protein eluted using PBS with 200 mM NaCl, 300 mM imidazole pH 7.4, and 15 mM b-mercaptoethanol. Fractions were
analysed by SDS-PAGE, pooled and dialyzed against PBS with 200 mM NaCl and 1 mM DTT. His-tagged hMYO6 CBD (aa 1034–
1294) was prepared as described previously (Spudich et al., 2007) with the following modifications after application to the Ni-NTA
column of washing with PBS containing 100 mM imidazole at pH 7.4 and eluting with PBS containing 300 mM imidazole at
pH 7.4. GST-tagged hMYO6 CBD (aa 1034–1294) was prepared as described for GST-tagged MYO6 fusion proteins (Buss et al.,
1998) and purified on glutathione sepharose 4B (GE Healthcare) according to the manufacturer’s instructions.
Ubiquitin Binding and Competition Assays
His-MYO6 CBD (500 nM) or His-TAX1BP1 (500 nM) were bound to Ni-NTA agarose (Qiagen) in Tris binding buffer (25 mM Tris-HCl,
pH 7.4, 250 mM NaCl, 0.1% Triton, 1 mM DTT, BSA 0.25 mg/ml). Increasing concentrations of K63 or K11 Ub4 chains were added
(25, 50 or 100 nM) and the samples incubated at 4C for 30min on a rotator. The resins werewashed five timeswith Tris binding buffer
and proteins bound visualised by Western blotting. Competition binding assays were performed by first incubating the GST-MYO6
CBD (300 nM) and K63 Ub4 (150 nM) with glutathione sepharose 4B in Tris binding buffer at 4C for 30 min. The resins were then
washed five times before incubation with increasing concentrations of His-TAX1BP1 (150 nM, 300 nM, 600 M, 1.2 mM or 2.4 mM)
for 30 min at 4C. Finally, the resins were washed five times with Tris binding buffer and proteins bound visualised by Western
blotting.
Presentation of Data
All graphs were produced using Prism (GraphPad) software. Images were processed in Photoshop (Adobe) and assembled into
figures using InDesign or Illustrator (Adobe).
QUANTIFICATION AND STATISTICAL ANALYSIS
Image Analysis
For co-localization analysis of confocal images, the Pearson’s correlation coefficient automatically thresholded using the Costes
et al. method (Costes et al., 2004) was quantified using Volocity software v6.3 (PerkinElmer). To quantitate the percentage of cells
withMYO6 or F-actin onmitochondria, widefield images were scored for the presence or absence ofMYO6 or actin onmitochondria.
For themitochondrial morphology quantitation, widefield images were scored according to three categories: clustered, refusing, and
network. For quantitation of SR-SIM images, 5 mm2 region of interests for mitochondria (with or without F-actin cages) were chosen
and themitochondrial area was determined using the ‘analyse particles’ function with aminimum area of 0.05 mm2 in Fiji (NIH). For EM
quantitation, cell areas (57.46 mm2) were randomly selected on32900 zoom and the number of phagophores and autophagosomes
containing either mitochondria or ER/cytoplasm were counted (Yoshii et al., 2011).
Statistics
Statistics were calculated using a Student’s t test and one- or two-way analysis of variance (ANOVA) followed by a Bonferroni
multiple-comparison post-hoc test. In each figure legend, the statistical parameters are stated: how the data is represented
(mean ± S.E.M), the number of independent experiments (nR3), and the statistical test used to obtain p values and determine
significance.Developmental Cell 44, 484–499.e1–e6, February 26, 2018 e6
